Milind Javle (@javlemilind) 's Twitter Profile
Milind Javle

@javlemilind

Hubert L and Olive Stringer Professor GI Medical Oncology and Attending Physician, MD Anderson Cancer Center
Chair, NCI Task Force Hepatobiliary Cancers

ID: 1357532036475596800

calendar_today05-02-2021 03:30:48

773 Tweet

1,1K Followers

370 Following

Milind Javle (@javlemilind) 's Twitter Profile Photo

Interesting abstract released for Asco 2024. Liver transplant for CRC: first positive prospective trial. Ready for prime time? Exciting work ILTS Dr. Cathy Eng Sudha Kodali Gonzalo Sapisochin meetings.asco.org/abstracts-pres…

Arndt Vogel (@arndtvogel) 's Twitter Profile Photo

🔥off the press: Durvalumab plus GemCis in advanced biliary tract cancer: TOPAZ-1 phs-3 The Lancet Gastroenterology & Hepatology 🧐Updated OS data, including long-term survivors & OS by ORR 👇my personal Share Link: authors.elsevier.com/c/1jAbO8nByrCh… ESMO - Eur. Oncology EASLnews ILCA Cholangiocarcinoma Foundation #livertwitter

🔥off the press: Durvalumab plus GemCis in advanced biliary tract cancer:  TOPAZ-1 phs-3
<a href="/LancetGastroHep/">The Lancet Gastroenterology & Hepatology</a> 
🧐Updated OS data, including long-term survivors &amp; OS by ORR 
👇my personal Share Link:
authors.elsevier.com/c/1jAbO8nByrCh…
<a href="/myESMO/">ESMO - Eur. Oncology</a> <a href="/EASLnews/">EASLnews</a> <a href="/ILCAnews/">ILCA</a> <a href="/curecc/">Cholangiocarcinoma Foundation</a> #livertwitter
Cholangiocarcinoma Foundation (@curecc) 's Twitter Profile Photo

CCF is pleased to share a newly published paper in the The Lancet Gastroenterology & Hepatology with updated survival data from the TOPAZ-1 trial, which established durvalumab as the standard of care immunotherapy when added to cisplatin and gemcitabine chemotherapy. thelancet.com/journals/langa…

jorge_adeva_MD (@cofiadeva) 's Twitter Profile Photo

Thank you #postcao2024 for giving me the opportunity to present my best of #ASCO24 in #digestivenocolorectal in Madrid. Lots of new data and hope for our patients. See you next week in my very loved Barcelona.

Thank you #postcao2024 for giving me the opportunity to present my best of #ASCO24 in #digestivenocolorectal in Madrid. Lots of new data and hope for our patients. See you next week in my very loved Barcelona.
Milind Javle (@javlemilind) 's Twitter Profile Photo

Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers aacrjournals.org/cancerdiscover…

Milind Javle (@javlemilind) 's Twitter Profile Photo

Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study ⁦Cholangiocarcinoma Foundation⁩ ⁦ENSCCA_2020⁩ browzine.com/articles/61587…

IDEOlogy Health (@ideologyhealth) 's Twitter Profile Photo

Released today: 📣 New Sound Bites video on the TOPAZ-1 trial in the treatment of BTC presented by Dr. Milind Javle ➡️ hubs.la/Q02DS-W80 #TOPAZ1 #oncologynews

Anirban Maitra (@aiims1742) 's Twitter Profile Photo

Impressive resource & dataset for those researching #Cholangiocarcinoma & other #BileDuct cancers. Preprint from Francisca Vazquez Gaddy Getz & Nabeel Bardeesy Mass General Cancer Center Broad Institute. Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and

Impressive resource &amp; dataset for those researching #Cholangiocarcinoma &amp; other #BileDuct cancers. Preprint from <a href="/DrFranVazquez/">Francisca Vazquez</a> <a href="/gaddyg/">Gaddy Getz</a> &amp; Nabeel Bardeesy <a href="/MGHCancerCenter/">Mass General Cancer Center</a> <a href="/broadinstitute/">Broad Institute</a>.
Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and
Paolo Tarantino (@ptarantinomd) 's Twitter Profile Photo

Results from DESTINY-CRC02 published in The Lancet Oncology. Among patients with pretreated, HER2+ mCRC, the lower dose of T-DXd (5.4 mg/kg) led to higher ORR and longer PFS than the higher dose (6.4 mg/kg), with nearly half the rate of ILD. Less can be more. thelancet.com/journals/lanon…

Results from DESTINY-CRC02 published in <a href="/TheLancetOncol/">The Lancet Oncology</a>. Among patients with pretreated, HER2+ mCRC, the lower dose of T-DXd (5.4 mg/kg) led to higher ORR and longer PFS than the higher dose (6.4 mg/kg), with nearly half the rate of ILD. Less can be more. thelancet.com/journals/lanon…
Albert Koong, MD PhD (@ackoongmdphd) 's Twitter Profile Photo

Congrats Ethan Ludmir MD and Chad Tang, MD! This MD Anderson Cancer Center P2 randomized study shows PFS of 10.3 mo vs. 2.5 mo in #PancreasCancer pts with oligometastatic dz treated with metastasis-directed therapy+sys tx vs. sys tx alone. #radonc #endcancer ascopubs.org/doi/10.1200/JC…

JCO Precision Oncology (@jcopo_asco) 's Twitter Profile Photo

Molecular Differences With Therapeutic Implications in Early-Onset Compared With Average-Onset Biliary Tract Cancers: ascopubs.org/doi/abs/10.120… @thejusjay Alok Khorana, MD #gicsm

Milind Javle (@javlemilind) 's Twitter Profile Photo

The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma | Nature Communications. Interesting article on Lenvatinib nature.com/articles/s4146…

Syed A. Ahmad (@syedaahmad5) 's Twitter Profile Photo

Restrictive Strategy vs Usual Care for Cholecystectomy in Patients With Abdominal Pain and Gallstones: 5-Year Follow-Up of the SECURE Randomized Clinical Trial ⁦JAMA Surgery⁩ jamanetwork.com/journals/jamas…